Bayer HealthCare Selects Genedata´s Bioinformatic Platform for its Target Research and Biomarker Activities

Basel, Switzerland, March 7, 2006
  • Multi-site integration of Genedata Expressionist® and Phylosopher® with Bayer HealthCare’s research informatics infrastructure
  • Mechanistic analysis of cardiovascular and cancer biomarker genes
  • Gene expression data used for prediction of toxicological effects

Genedata today announced the expansion of its collaboration with Bayer HealthCare to include multiple sites in Germany and the US. Genedata will deliver a software solution for characterizing targets and biomarkers.

“Genedata have helped resolve bottlenecks in our research processes, an achievement reflecting their sound grasp of drug discovery,” said Professor Andreas Busch, Head of Global Drug Discovery, Bayer HealthCare. The collaboration has expanded to complement the activities of Bayer HealthCare’s target and biomarker research program. Biomarkers
will help identify compounds likely to be effective at later drug development stages, enabling Bayer HealthCare to focus its attention on the most promising therapeutic leads.

“In addition to strong software functionality, we require scalability and solid result information management”, explained Dr. Joe Catino, Head of Discovery US, Bayer Pharmaceuticals Corp. in West Haven. Genedata’s solutions incorporate industry-standard database technologies with an advanced three tier client-server architecture. This has facilitated efficient deployment and integration with Bayer HealthCare’s global research informatics infrastructure.

“We are delighted that Bayer HealthCare has chosen Genedata’s proven IT solutions to support its target and biomarker research efforts”, said Dr. Othmar Pfannes, Chairman and President of Genedata. Earlier phases of the collaboration have been expanded to create a global research informatics solution for Bayer Healthcare. Dr. Pfannes added, “The collaboration demonstrates the usefulness of Genedata Expressionist® and Genedata Phylosopher® for target identification, diagnostics, toxicology and biomarker studies.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US.


Allison Kurz
Marketing & Communications
Phone: +41 61 511 8459

Jackie Thrasivoulos
Public Relations
Phone: +1 508 881 3109


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.